Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High – What’s Next?

Krystal Biotech, Inc. (NASDAQ:KRYS) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $319.60 and last traded at $315.5830, with a volume of 71079 shares traded. The stock had previously closed at $309.75.

Analyst Ratings Changes

A number of equities analysts have issued reports on KRYS shares. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Wolfe Research started coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating for the company. HC Wainwright reissued a “buy” rating and set a $310.00 price target on shares of Krystal Biotech in a research report on Monday, June 1st. Citigroup lifted their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Jefferies Financial Group lifted their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $324.11.

Krystal Biotech Stock Performance

The business’s 50 day moving average is $284.68 and its 200-day moving average is $266.01. The stock has a market cap of $9.23 billion, a price-to-earnings ratio of 41.79 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The firm had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of KRYS. Royal Bank of Canada grew its holdings in shares of Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after buying an additional 964 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after buying an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after buying an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Krystal Biotech during the 1st quarter valued at about $218,000. Finally, Cetera Investment Advisers boosted its position in shares of Krystal Biotech by 107.9% during the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after acquiring an additional 2,255 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.